Sex differences and serotonergic mechanisms in the behavioural effects of psilocin

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023752%3A_____%2F16%3A43914800" target="_blank" >RIV/00023752:_____/16:43914800 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11120/16:43910988

Výsledek na webu

<a href="http://journals.lww.com/behaviouralpharm/Abstract/2016/06000/Sex_differences_and_serotonergic_mechanisms_in_the.1.aspx" target="_blank" >http://journals.lww.com/behaviouralpharm/Abstract/2016/06000/Sex_differences_and_serotonergic_mechanisms_in_the.1.aspx</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1097/FBP.0000000000000198" target="_blank" >10.1097/FBP.0000000000000198</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Sex differences and serotonergic mechanisms in the behavioural effects of psilocin

Popis výsledku v původním jazyce

Psilocybin has recently attracted a great deal of attention as a clinical research and therapeutic tool. The aim of this paper is to bridge two major knowledge gaps regarding its behavioural pharmacology i.e. sex differences and the underlying receptor mechanisms. We used psilocin (0.25, 1 and 4 mg/kg), an active metabolite of psilocybin, in two behavioural paradigms - the open field test and the test of prepulse inhibition (PPI) of acoustic startle reaction. Sex differences were evaluated with respect to the phase of the female cycle. The contribution of serotonin receptors in the behavioural action was tested in male rats with selective serotonin receptor antagonists: 5-HT1A receptor antagonist (WAY100635 1 mg/kg), 5-HT2A receptor antagonist (MDL100907 0.5 mg/kg), 5-HT2B receptor antagonist (SB215505 1 mg/kg) and 5-HT2C receptor antagonist (SB242084 1 mg/kg). Psilocin induced dose dependent inhibition of locomotion and suppression of normal behaviour of rats (behavioural serotonin syndrome, impaired PPI). The effects were most pronounced in male rats, female rats were affected by psilocin treatment to a lesser degree. The inhibition of locomotion was normalized by 5-HT1A and 5-HT2B/C antagonists; however PPI was not affected significantly by antagonists used. Our findings highlight an important issue of sex specific reactions to psilocin and that apart from 5-HT2A mediated effects 5-HT1A and 5-HT2C/B receptors also play an important role. These findings have further implications for recent clinical trials.

Název v anglickém jazyce

Sex differences and serotonergic mechanisms in the behavioural effects of psilocin

Popis výsledku anglicky

Psilocybin has recently attracted a great deal of attention as a clinical research and therapeutic tool. The aim of this paper is to bridge two major knowledge gaps regarding its behavioural pharmacology i.e. sex differences and the underlying receptor mechanisms. We used psilocin (0.25, 1 and 4 mg/kg), an active metabolite of psilocybin, in two behavioural paradigms - the open field test and the test of prepulse inhibition (PPI) of acoustic startle reaction. Sex differences were evaluated with respect to the phase of the female cycle. The contribution of serotonin receptors in the behavioural action was tested in male rats with selective serotonin receptor antagonists: 5-HT1A receptor antagonist (WAY100635 1 mg/kg), 5-HT2A receptor antagonist (MDL100907 0.5 mg/kg), 5-HT2B receptor antagonist (SB215505 1 mg/kg) and 5-HT2C receptor antagonist (SB242084 1 mg/kg). Psilocin induced dose dependent inhibition of locomotion and suppression of normal behaviour of rats (behavioural serotonin syndrome, impaired PPI). The effects were most pronounced in male rats, female rats were affected by psilocin treatment to a lesser degree. The inhibition of locomotion was normalized by 5-HT1A and 5-HT2B/C antagonists; however PPI was not affected significantly by antagonists used. Our findings highlight an important issue of sex specific reactions to psilocin and that apart from 5-HT2A mediated effects 5-HT1A and 5-HT2C/B receptors also play an important role. These findings have further implications for recent clinical trials.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FL - Psychiatrie, sexuologie

OECD FORD obor

—

Projekt

Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2016

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Behavioural Pharmacology

ISSN

0955-8810

e-ISSN

—

Svazek periodika

27

Číslo periodika v rámci svazku

4

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

12

Strana od-do

309-320

Kód UT WoS článku

000375627500001

EID výsledku v databázi Scopus

2-s2.0-84965046020